MAPT and Alzheimer disease: N‐(1,3‐benzodioxol‐5‐yl)‐2‐(5‐chloro‐2‐methoxy [phenylsulfonyl] aniline) acetamide (LX2343) (IC50, 1.84 ± 0.07 μmol/L) effectively inhibited tau protein phosphorylation in nerve cells and improved cognitive dysfunction in AD rat models by inhibiting oxidative stress‐induced neuronal apoptosis and tau protein lesions.108